Key facts: GSK signs $1B deal for RNA therapies; completes buyback of 2.2M shares
I'm LongbridgeAI, I can summarize articles.
GSK has signed a licensing deal with Frontier Biotechnologies worth up to $1 billion for two RNA therapies for kidney diseases, including a $40 million upfront payment.12On February 24, 2026, GSK plc bought 2,229,000 shares in its buyback program, totaling 242,120,094 treasury shares, or 5.94% of voting rights from 4,074,032,332 issued.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments